Literature DB >> 32560898

Limitations of Randomized Clinical Trials.

John B Kostis1, Jeanne M Dobrzynski2.   

Abstract

Randomized clinical trials are essential for determining the efficacy of interventions, but have limitations. The types of limitations discussed in this review may be grouped in 11 categories including incorrect statistical inference, low internal or external validity, misinterpretation of the difference between frequentist and Bayesian statistical approaches, publication bias, that healthy persons with a given condition participate in clinical trials although they are not representative of the population as a whole, the rather short duration (3 to 5 years) that does not give correct estimates of the lifetime effects of the interventions or the legacy effect when participants who receive active therapy derive residual benefit after the end of the study when all participants receive active medication and the tension between the generalizability of the evidence versus the reliability of the findings of different types of clinical trials and the difficulty in applying the findings of randomized clinical trials to individual patients. These limitations are described and illustrated by examples and figures from the literature. In conclusion, this review will be useful to clinical trialists, clinical trial participants and regulatory agents.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32560898     DOI: 10.1016/j.amjcard.2020.05.011

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Reply to "Recommendation on an updated standardization of serum magnesium reference ranges," Jeroen H.F. de Baaij et al.

Authors:  Rhian M Touyz; Federica Wolf; Jeanette A Maier; Andrea Rosanoff; Christina West; Ronald J Elin; Oliver Micke; Shadi Baniasadi; Mario Barbagallo; Emily Campbell; Fu-Chou Cheng; Rebecca B Costello; Claudia Gamboa-Gomez; Fernando Guerrero-Romero; Nana Gletsu-Miller; Bodo von Ehrlich; Stefano Iotti; Ka Kahe; Dae Jung Kim; Klaus Kisters; Martin Kolisek; Anton Kraus; Magdalena Maj-Zurawska; Lucia Merolle; Mihai Nechifor; Guitti Pourdowlat; Michael Shechter; Yiqing Song; Yee Ping Teoh; Taylor C Wallace; Kuninobu Yokota
Journal:  Eur J Nutr       Date:  2022-10-07       Impact factor: 4.865

2.  An empirical evaluation of the impact scenario of pooling bodies of evidence from randomized controlled trials and cohort studies in medical research.

Authors:  Nils Bröckelmann; Julia Stadelmaier; Louisa Harms; Charlotte Kubiak; Jessica Beyerbach; Martin Wolkewitz; Jörg J Meerpohl; Lukas Schwingshackl
Journal:  BMC Med       Date:  2022-10-24       Impact factor: 11.150

3.  Emulation of the control cohort of a randomized controlled trial in pediatric kidney transplantation with Real-World Data from the CERTAIN Registry.

Authors:  Christian Patry; Lukas D Sauer; Britta Höcker; Burkhard Tönshoff; Anja Sander; Kai Krupka; Alexander Fichtner; Jolanda Brezinski; Yvonne Geissbühler; Elodie Aubrun; Anna Grinienko; Luca Dello Strologo; Dieter Haffner; Jun Oh; Ryszard Grenda; Lars Pape; Rezan Topaloğlu; Lutz T Weber; Antonia Bouts; Jon Jin Kim; Agnieszka Prytula; Jens König; Mohan Shenoy
Journal:  Pediatr Nephrol       Date:  2022-10-20       Impact factor: 3.651

4.  Critical Question in Cardiovascular Risk: Can we use clinical trials to improve the outcomes of patients with hypertension?

Authors:  John B Kostis
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2021-09-20

Review 5.  Minimally Invasive Surgery for Cervical Cancer in Light of the LACC Trial: What Have We Learned?

Authors:  Omar Touhami; Marie Plante
Journal:  Curr Oncol       Date:  2022-02-14       Impact factor: 3.677

Review 6.  Pragmatic Clinical Studies: An Emerging Clinical Research Discipline for Improving Evidence-Based Practice of Cardiovascular Diseases in Asia.

Authors:  Dong Zhao; Chen Yao
Journal:  Korean Circ J       Date:  2022-06       Impact factor: 3.101

7.  Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?

Authors:  Eulalie Courcelles; Jean-Pierre Boissel; Jacques Massol; Ingrid Klingmann; Riad Kahoul; Marc Hommel; Emmanuel Pham; Alexander Kulesza
Journal:  Front Med Technol       Date:  2022-02-24

8.  Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.

Authors:  Yuwen Qi; Yaxing Zhang; Yuying Shi; Shijie Yao; Mengyuan Dai; Hongbing Cai
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.